Moleculin announces FDA approval of 3 Rare pediatric disease designations for WP1066

▴ Moleculin announces FDA approval of 3 Rare pediatric disease designations for WP1066
The designation entitles Moleculin to receive a transferrable Priority Review Voucher (PRV) upon New Drug Approval (NDA)

Moleculin Biotech, Inc.,, a clinical-stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumours and viruses, announced that the US Food and Drug Administration (FDA) has approved its request for a "Rare Pediatric Disease" designation for its drug candidate WP1066. The designation entitles Moleculin to receive a transferrable Priority Review Voucher (PRV) upon New Drug Approval (NDA) for each of three indications, including diffuse intrinsic pontine glioma (DIPG), medulloblastoma and atypical teratoid rhabdoid tumour.

"The early activity we are seeing in WP1066 is both unexpected and encouraging," commented Walter Klemp, Chairman and CEO of Moleculin. "The approval of these three Rare Pediatric Disease designations is a reminder of just how important our efforts are to potentially help children with brain tumours."

Mr. Klemp concluded: "It is also important for investors to understand the implications of the PRVs or Priority Review Vouchers. These vouchers are issued upon drug approval of the rare disease indication from the FDA and, once issued, can be transferred to other drug developers. These PRVs have historically had tremendous value and have been recently sold for up to $100 million or more. For Moleculin to have the potential for three of them is noteworthy indeed."

Tags : #Moleculin #FDAApproval #FDANews #WP1066 #Medulloblastoma #TeratoidRhabdoidTumour #LatestPharmaNewsDec3

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

FTCCI with support from the Ministry of MSME, Govt of Inia to host an International Conference on Shipping and Logistics at HICC on 22nd MarchMarch 18, 2024
Rotary donates Upgraded Neonatal ICU at Niloufer Hospital worth Rs 48 LakhsMarch 18, 2024
Fateh Education shares insight into Financial strategies and Post-Study employment goals of students aspiring to study abroadMarch 18, 2024
Empowering Communities: We Care Foundation Hosts 3rd Edition of I - Inspiration Awards, Championing Health, Finance, and Cyber WellnessMarch 18, 2024
Safeguarding Spectators: Medulance Partners with Zomato Live for On-site Medical Assistance at ZomalandMarch 18, 2024
Unsung hero, Chindu Yakshaganam theatre artist, Padma Shri Gaddam Sammaiah graced the 17th Annual Day of Anurag UniversityMarch 18, 2024
Multidisciplinary Approach at Citizens Specialty Hospital Saved 35-year-old Patient with Disc Prolapse following a recent Heart AttackMarch 18, 2024
Asia Pacific region’s First Patellofemoral Joint surgery is successful in India.March 18, 2024
FDA Greenlights Lupin's Varenicline Tablets: A Game-Changer in Smoking Cessation TherapyMarch 18, 2024
Deciphering STAP-1: A Promising Target for Immune-Related DiseasesMarch 18, 2024
The Gut-Brain Connection: How Gut Bacteria Shape Immunity and Prevent Allergic Reactions in NewbornsMarch 18, 2024
IIIT Hyderabad’s Annual R&D Showcase beginsMarch 16, 2024
Exploring New Horizons: The Role of Copper and Resveratrol in Cancer CareMarch 16, 2024
Expanding Healthcare Infrastructure: Delhi’s Ambitious EndeavourMarch 16, 2024
FTCCI's Tourism Committee brands cab drivers as ambassadors for tourism and trains 200 cab drivers at GMR Airport in Etiquette, Hygiene, First Aid, CPR and the English languageMarch 16, 2024
Musing of a Teenage Girl, a poetry book authored by a 14 years girl Sanjana Somavarapu releasedMarch 16, 2024
5th Edition FTCCI HR Awards 2023 Presented for best practices in people processesMarch 15, 2024
FTCCI Delegation visits T-WorksMarch 15, 2024
Debunking Myths: ICMR Study Disproves COVID Vaccine Link to Sudden DeathsMarch 15, 2024
Beware of Rhodamine-B: Several States in India Implement Ban on Artificial Food Coloring AgentsMarch 15, 2024